Overview
Ember Health provides ketamine infusion therapy for depression, offered to patients referred by healthcare providers or who contact the clinic directly. The core treatment consists of four 40-minute infusions over two weeks, given as part of a broader mental health care plan in line with American Psychiatric Association guidelines. Infusions are delivered in a structured sequence with close monitoring of patient outcomes, and the effort is supported by ongoing data collection and participation in clinical research. The company differentiates itself by emphasizing evidence-based care and outcomes tracking within the existing mental health system, aiming to improve depression relief through a standardized protocol and contribute to clinical knowledge.
Work here?Claim your company
Simplify's take
What believers are saying
- Curative coverage on October 9, 2026 should reduce patient price friction immediately.
- Ember's Brooklyn Heights cash pricing of $550 per infusion proves transparent, repeatable revenue.
- October 2026 location pages show five active NYC clinics, supporting local brand density.
What critics are saying
- Tribeca was temporarily closed on October 5, 2026, signaling site-level volatility.
- Ketamine remains generic and uninsured patients face reimbursement friction, limiting scale beyond affluent markets.
- Aetna, UnitedHealthcare, and Cigna can lock up employer networks first, starving Ember's referral pipeline.
What makes Ember Health unique
- Ember Health built a dedicated NYC ketamine network across Brooklyn and Manhattan by October 2026.
- Ember Health offers 1:1 IV monitoring, emergency-medicine-trained physicians, and clinical psychological support.
- Ember Health's October 9, 2026 Curative contract gives it rare in-network ketamine access.
Help us improve and share your feedback! Did you find this helpful?